PRPH · XBRL financial data

ProPhase Labs financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PRPH's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	8,365	3,499*	3,634	2,474	3,146	(2,484)*	1,431	1,247	883	784*	1,169	1,011
Cost of goods and services sold	6,038	6,555*	4,067	2,950	3,311	(3,408)*	905	513	1,006	537*	874	785
Gross profit	2,327	(3,056)*	(433)	(476)	(165)	924*	526	734	(123)	247*	295	226
Research and development	428	274*	272	139	122	61*	97	4	6	0*	—	—
General and administrative	8,245	8,022*	7,593	7,212	7,650	15,430*	4,092	4,624	4,635	5,973*	2,721	2,871
Total operating expenses	8,805	8,296*	7,865	7,351	7,772	15,491*	4,189	4,628	4,641	5,973*	2,721	2,871
Operating income (loss)	(6,478)	(11,352)*	(8,298)	(7,827)	(7,937)	(14,567)*	(3,663)	(3,894)	(4,764)	(5,726)*	(2,426)	(2,645)
Interest expense	275	494*	515	643	1,158	1,034*	539	587	1,549	4,258*	651	791
Other income (expense)	(33)	142*	(18)	30	0	(30)*	(45)	0	0	(174)*	(129)	59
Income tax expense (benefit)	(1,644)	(2,914)*	(2,566)	(2,287)	(2,508)	14,556*	0	779	(157)	(622)*	1,374	12
Net income (loss)	(5,141)	(8,751)*	(6,265)	(6,153)	(6,587)	(34,359)*	3,966	(4,472)	(6,839)	(7,398)*	(5,175)	(3,051)
Earnings per share, basic‡ USD per share	(3.00)	—	(3.50)	(3.30)	(3.50)	—	1.10	(1.10)	(1.60)	—	(0.42)	(0.22)
Earnings per share, diluted‡ USD per share	(3.00)	—	(3.50)	(3.30)	(3.50)	—	1.10	(1.10)	(1.60)	—	(0.42)	(0.22)
Weighted average shares, basic‡ thousands of shares	1,718	—	1,805	1,889	1,908	—	3,523	4,154	4,154	—	12,317	14,016
Weighted average shares, diluted‡ thousands of shares	1,718	—	1,805	1,889	1,908	—	3,523	4,154	4,154	—	12,317	14,016

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.
† Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (PRPH's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	702	1,609	1,175	1,780	501	678	88	169	405	90	31	20
Marketable securities	2,565	3,127	58	1	2	0	—	2	—	0	—	—
Accounts receivable	38,642	36,313	35,116	32,937	31,638	20,058	20,204	20,086	3,284	1,536	1,543	1,543
Inventory	5,054	3,841	3,758	3,867	3,966	1,143	1,145	830	266	70	70	70
Prepaid and other current assets	2,831	2,155	4,377	4,973	5,535	2,615	3,333	3,484	3,818	1,454	1,206	1,169
Total current assets	49,794	47,585	45,045	44,143	42,235	30,637	24,770	24,571	7,773	3,150	2,850	2,802
Property and equipment, net	13,163	—	—	—	—	—	—	—	—	2,032	1,709	1,392
Right-of-use asset	4,680	4,572	4,462	4,350	4,234	4,115	3,994	45	0	0	—	—
Goodwill	5,231	5,231	5,231	5,231	5,231	5,231	5,231	5,231	3,968	3,968	3,968	3,968
Total assets	91,710	91,927	90,032	93,678	91,808	63,200	50,111	42,041	65,702	59,871	58,467	57,409
Accounts payable	5,467	9,383	11,759	13,628	15,459	13,717	13,326	15,032	—	—	—	—
Accrued liabilities	—	1,445	—	—	—	1,945	—	—	—	1,885	—	—
Total current liabilities	16,406	20,857	23,907	28,012	28,698	32,134	24,052	25,626	55,287	53,081	55,666	58,087
Long-term debt	—	2,924	—	—	—	—	—	—	—	—	—	—
Lease liability, non-current	4,345	4,237	4,122	4,005	3,663	3,762	3,695	0	0	0	—	—
Total liabilities	35,282	42,544	45,165	49,602	53,682	55,847	34,993	30,605	58,841	56,363	58,902	60,520
Retained earnings (accumulated deficit)	3,722	(5,029)	(11,294)	(17,447)	(24,034)	(58,393)	(54,427)	(58,899)	(65,738)	(73,136)	(78,311)	(81,362)
Total stockholders' equity	56,428	49,383	44,867	44,076	38,126	7,353	15,118	11,436	6,861	3,508	(435)	(3,111)
Total liabilities and equity	91,710	91,927	90,032	93,678	91,808	63,200	50,111	42,041	65,702	59,871	58,467	57,409
Common shares outstanding (cover page)‡ thousands of shares	1,805	1,805	1,908	1,908	2,387	4,188	4,154	4,154	4,618	14,016	14,016	15,593

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.
† Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (PRPH's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(5,141)	(8,751)*	(6,265)	(6,153)	(6,587)	(34,359)*	3,966	(4,472)	(6,839)	(7,398)*	(5,175)	(3,051)
Stock-based compensation	857*	676*	1,589	796*	636*	617*	521	508*	431*	433*	390	375*
Depreciation and amortization	1,796*	1,842*	1,686	1,617*	2,390*	494*	1,482	1,349*	1,038*	963*	962	963*
Net cash from operating activities	(4,654)*	(213)*	(5,119)	(4,818)*	(4,030)*	(3,571)*	(3,381)	(247)*	(3,486)*	(1,230)*	(748)	(78)*
Net cash from investing activities	332*	(1,264)*	2,435	124*	(97)*	(40)*	853	67*	0*	0*	12	0*
Proceeds from issuing common stock	0*	0*	0	4,624*	0*	2,970*	3,278	280*	0*	0*	41	0*
Share repurchases	0*	0*	0	0*	0*	0*	—	—	—	—	—	—
Dividends paid	0*	0*	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	1,200*	2,924*	2,271	5,323*	2,856*	3,735*	1,938	261*	3,722*	915*	677	67*
Net change in cash	(3,122)*	1,447*	(413)	629*	(1,271)*	124*	(590)	81*	236*	(315)*	(59)	(11)*

† Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
X4 Pharmaceuticals	195,095	2,400	(20,788)*	99.1M	9.4 quarters	Q2 FY26 10-QJun 30, 2026
CalciMedica	18,617	not reported	(4,620)*	34.1M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Lipocine	4,979	190	(3,028)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.